Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved GSK’s Hibsago (bepirovirsen), an antisense oligonucleotide (ASO), as a functional cure for chronic hepatitis B (CHB) virus infection.  It is approved in adult patients who have received at least six months of prior nucleos(t)ide analogue therapy and meet pre-defined viral markers.   This is the first […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!